Discontinued — last reported Q2 '19
West Pharmaceutical Services Unrecognized tax benefits increased by 15.3% to $64.70M in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase suggests more aggressive tax positions or increased scrutiny from tax authorities, while a decrease indicates resolution of tax uncertainties.
Represents the total amount of tax benefits that have been taken or are expected to be taken in tax returns but have not...
Standard disclosure for large multinational corporations; peers with complex global tax structures typically report significant balances.
other_unrecognized_tax_benefits| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $56.10M | $64.70M |
| QoQ Change | — | +15.3% |